Brian Lian - 17 Apr 2023 Form 4 Insider Report for Viking Therapeutics, Inc. (VKTX)

Role: President & CEO, Director
Signature: /s/ Michael Morneau, as Attorney-in-Fact
Issuer symbol: VKTX
Transactions as of: 17 Apr 2023
Net transactions value: -$2,901,016
Form type: 4
Filing time: 18 Apr 2023, 19:09:19 UTC
Previous filing: 13 Apr 2023
Next filing: 21 Apr 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VKTX	Common Stock, par value $0.00001 per share	Options Exercise	$268,750	+125,000	+5.4%	$2.15^*	2,432,963	17 Apr 2023	Direct	F1
transaction	VKTX	Common Stock, par value $0.00001 per share	Sale	$3,169,766	-155,000	-6.4%	$20.45	2,277,963	17 Apr 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VKTX	Stock Option (Right to Buy)	Options Exercise	$0	-125,000	-100%	$0.000000^*	0	17 Apr 2023	Common Stock	125,000	$2.15	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person.
F2	25% of the shares subject to the option vested on each anniversary of the grant date.